Analyst
Chief Scientist
Equibles does not estimate personal net worth.
Get an email with a short summary when Sarepta Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SRPT alertsLouise Rodino-Klapac is recorded as Analyst at Chief Scientist. Sarepta Therapeutics, Inc. reported in an 8-K filed July 16, 2025 that Louise Rodino-Klapac was appointed President, Research and Development and Technical Operations, effective July 16, 2025. The proxy statement of Sarepta Therapeutics, Inc. reports total compensation of $4,456,270 for Louise Rodino-Klapac in fiscal 2025, including a base salary of $752,505. Disclosed compensation is on record for 8 fiscal years. Louise Rodino-Klapac has spoken on 5 earnings calls and 1 other investor event across 1 company, most recently for Sarepta Therapeutics, Inc. on November 5, 2026. Sarepta Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Sarepta Therapeutics, Inc. includes Douglas Ingram (CEO and Board Member), Michael Severino, M.D. (CEO and Board Member), M. Kathleen Behrens (Chairman) and 7 others.
“On July 14, 2025, the Board appointed Ian Estepan as the Company's President and Chief Operating Officer, Louise Rodino-Klapac, Ph.D. as the Company's President, Research and Development and Technical Operations, and Ryan Wong as the Company's Executive Vice President, Chief Financial Officer, each effective as of July 16, 2025.”
“We believe the progress the Sirepta team has made these past few months represents significant advancements, positioning us to bring the very best therapies to patients.”
“As we move into the few last months of 2026, we remain excited for the science that underlies our rare disease portfolio and the data we're preparing to share with you soon.”
“So Cohort Aid of Endeavor is an open-label study in non-ambulatory. So this is about the non-ambulatory population. And so by definition for the study, we're looking for a 50% reduction in the rates of ALI.”
“Our diverse and advancing rare disease portfolio has always been driven by a core fundamental truth. Pursue the very best science and then follow where it leads.”
“I'm happy to share with you our progress over the last several months, beginning with our positive top-line three-year functional results from Part 1 treated in patients in EMBARC for study SRP9001301, our global randomized placebo-controlled Phase III study evaluating Levitas and ambulatory individuals with Duchenne.”
Proxy statement
Start not stated–present
Last confirmed April 24, 2026
Chief Scientist
Analyst
Source not stated
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Sarepta Therapeutics, Inc. (SRPT) | President, Research and Development and Technical Operations | $752,505 | $4,456,270 |
| 2024 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer | $666,706 | $2,737,283 |
| 2023 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer | $641,063 | $3,718,991 |
| 2022 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer | $616,962 | $3,941,777 |
| 2021 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer | $555,577 | $8,515,533 |
| 2020 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer ^^ | $495,590 | $7,269,883 |
| 2019 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer ^^ | — | — |
| 2018 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Chief Scientific Officer ^^ | — | — |
